Profile data is unavailable for this security.
About the company
Beijing Foyou Pharma Co Ltd is a China-based company principally engaged in the research, development, production and sale of pharmaceuticals and medical devices. The Company operates its businesses through two segments. The Pharmaceutical segment is primarily engaged in the research, development, production and sale of products such as Olmesartan Medoxomil Tablets, Trimetazidine Hydrochloride Tablets, and Atorvastatin Calcium Tablets. The Medical Device segment is primarily engaged in the research, development, production and sale of disposable oxygen tubes and other humidified oxygen inhalation devices. The Company's pharmaceutical preparations cover the fields of cardiovascular system, chronic kidney disease, skin disease, digestive system and others. The Company mainly operates its businesses in the domestic and overseas markets.
- Revenue in CNY (TTM)3.42bn
- Net income in CNY463.07m
- Incorporated1999
- Employees3.64k
- LocationBeijing Foyou Pharma Co LtdNo. 8 Guangyuan East Street,Tongzhou Industrial Development Zone, ToBEIJING 101113ChinaCHN
- Phone+86 1 065020399
- Fax+86 1 065021289
- Websitehttps://www.foyou.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cansino Biologics Inc | 971.83m | -142.03m | 11.23bn | 1.11k | -- | 2.99 | -- | 11.55 | -0.5455 | -0.5455 | 3.92 | 21.37 | 0.1271 | 0.5861 | 1.38 | 879,482.50 | -1.86 | -4.08 | -2.29 | -5.38 | 78.80 | 45.31 | -14.62 | -27.51 | 3.29 | -- | 0.2242 | -- | 137.01 | 226.43 | 74.45 | -- | 31.38 | -- |
| Zhejiang CONBA Pharmaceutical Co., Ltd. | 6.58bn | 687.99m | 11.23bn | 8.26k | 16.62 | 1.58 | -- | 1.71 | 0.2665 | 0.2665 | 2.54 | 2.80 | 0.6617 | 2.57 | 4.70 | 796,529.00 | 7.13 | 8.51 | 9.65 | 12.74 | 51.88 | 58.64 | 10.77 | 14.12 | 1.38 | -- | 0.0532 | 41.54 | -3.23 | -0.7594 | 5.21 | -- | 1.57 | -- |
| Chengdu Easton Biopharmaceuticals Co Ltd | 1.33bn | 241.37m | 11.37bn | 1.52k | 46.91 | 3.97 | -- | 8.55 | 1.37 | 1.37 | 7.55 | 16.23 | 0.3809 | 1.83 | 5.89 | 873,161.50 | 6.92 | 8.09 | 8.44 | 9.82 | 71.90 | 81.72 | 18.16 | 20.10 | 3.12 | -- | 0.0444 | 30.37 | 20.82 | 7.34 | 5.15 | 17.01 | 4.24 | -- |
| Mayinglong Pharmaceutical Group Co Ltd | 3.77bn | 571.60m | 11.66bn | 2.65k | 20.39 | 2.71 | -- | 3.09 | 1.33 | 1.33 | 8.75 | 9.97 | 0.7211 | 6.23 | 11.99 | 1,421,812.00 | 11.38 | 10.77 | 13.82 | 13.35 | 46.77 | 42.40 | 15.78 | 14.39 | 4.58 | -- | 0.0226 | 37.31 | 18.85 | 6.62 | 19.14 | 7.97 | 34.47 | 18.98 |
| Jiangxi Tianxin Pharmaceutical Co Ltd | 2.23bn | 617.04m | 11.82bn | 2.68k | 19.07 | 2.47 | -- | 5.31 | 1.42 | 1.42 | 5.11 | 10.93 | 0.3973 | 2.43 | 9.65 | 830,883.10 | 11.01 | 17.10 | 11.88 | 21.16 | 43.04 | 42.99 | 27.72 | 30.12 | 4.31 | -- | 0.0721 | 24.41 | 17.35 | 1.75 | 36.85 | -2.20 | 35.06 | -- |
| Beijing Foyou Pharma Co Ltd | 3.42bn | 463.07m | 12.17bn | 3.64k | 25.71 | 3.22 | -- | 3.56 | 0.9863 | 0.9863 | 7.28 | 7.87 | 0.733 | 3.27 | 9.59 | 938,316.50 | 9.99 | 12.53 | 12.82 | 17.64 | 65.17 | 68.01 | 13.62 | 13.02 | 2.52 | -- | 0.0077 | 33.16 | 3.17 | 7.28 | -0.0188 | 17.44 | 35.29 | -- |
| Henan Lingrui Pharmaceutical Co., Ltd. | 3.78bn | 799.61m | 12.18bn | 2.44k | 15.23 | 3.75 | -- | 3.22 | 1.41 | 1.41 | 6.67 | 5.73 | 0.711 | 1.89 | 8.06 | 1,553,625.00 | 15.08 | 11.90 | 25.52 | 18.89 | 79.26 | 74.36 | 21.21 | 16.46 | 0.9053 | -- | 0.1379 | 73.97 | 5.72 | 10.17 | 27.19 | 19.67 | 14.29 | 24.57 |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 9.84bn | 546.80m | 12.36bn | 7.99k | 21.58 | 1.45 | -- | 1.26 | 0.4778 | 0.4778 | 8.61 | 7.10 | 0.623 | 3.08 | 5.32 | 1,230,310.00 | 3.48 | 2.33 | 5.81 | 4.32 | 46.64 | 41.26 | 5.58 | 3.99 | 0.6646 | 5.33 | 0.2803 | 29.47 | -5.65 | -2.44 | 745.24 | 45.22 | -26.03 | 33.24 |
| Shenzhen Chipscreen Biosciences Co Ltd | 850.99m | 7.28m | 12.98bn | 1.06k | 1,781.20 | 7.84 | -- | 15.25 | 0.0179 | 0.0179 | 2.09 | 4.06 | 0.2441 | 2.40 | 4.06 | 802,822.70 | 0.2089 | 0.0036 | 0.2479 | 0.0042 | 85.48 | 91.31 | 0.8557 | 0.0181 | 1.79 | -0.6319 | 0.4834 | 0.00 | 25.63 | 30.51 | -228.97 | -- | 15.08 | -- |
Data as of Feb 13 2026. Currency figures normalised to Beijing Foyou Pharma Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
1.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 1.33m | 0.28% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 994.00k | 0.21% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 796.50k | 0.17% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 761.02k | 0.16% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 602.10k | 0.13% |
| CCB Principal Asset Management Co., Ltd.as of 30 Jun 2025 | 261.80k | 0.06% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2025 | 235.30k | 0.05% |
| FIL Investments Internationalas of 30 Jun 2025 | 235.29k | 0.05% |
| Xingyin Fund Management Co., Ltd.as of 30 Jun 2025 | 143.80k | 0.03% |
| Essence Fund Co., Ltd.as of 30 Jun 2025 | 96.40k | 0.02% |
More ▼
Data from 30 Jun 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
